一分钟看懂
这是一项关于Malignant Neoplasm的I 期 / II 期研究，登记的药物或干预包括Ifinatamab Deruxtecan，当前状态为招募中。登记地点显示中国Los Angeles、Aurora、Iowa City、Boston等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ifinatamab Deruxtecan · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Children's Hospital Los Angeles ( Site 4006) · Los Angeles
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 4016) · Aurora
- University of Iowa Hospitals ( Site 4017) · Iowa City
- Dana Farber Cancer Center ( Site 4013) · Boston
- Corewell Health ( Site 4001) · Grand Rapids
- Rutgers Cancer Institute of New Jersey ( Site 4008) · New Brunswick
- Memorial Sloan Kettering Cancer Center ( Site 4010) · New York
- New York Medical College ( Site 4023) · Valhalla
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 4003) · Fargo
- Children's Hospital of Philadelphia (CHOP) ( Site 4021) · Philadelphia
- Sanford Children's Hospital ( Site 4015) · Sioux Falls
- University of Texas M.D. Anderson Cancer Center ( Site 4007) · Houston
- Intermountain - Primary Children's Hospital ( Site 4014) · Salt Lake City
- UZ Gent ( Site 4428) · Ghent
- Rigshospitalet ( Site 4467) · Copenhagen
- Bordeaux University Hospital - Pellegrin ( Site 4105) · Bordeaux
- Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 4104) · Nantes
- CENTRE LEON BERARD ( Site 4100) · Lyon
- Rambam Health Care Campus ( Site 4674) · Haifa
- Sheba Medical Center ( Site 4675) · Ramat Gan
- Seoul National University Hospital-Pediatrics ( Site 4972) · Seoul
- Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 4973) · Seoul
- Hospital Sant Joan de Déu ( Site 4717) · Esplugues de Llobregat
- Hospital Niño Jesús ( Site 4715) · Madrid
- Hospital Universitari Vall d Hebron ( Site 4716) · Barcelona
- Sahlgrenska Universitetssjukhuset ( Site 4634) · Gothenburg
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * In Part 1, participant has recurrent or relapsed, refractory solid tumors (excluding primary central nervous system (CNS)); and in Part 2, participant has recurrent or relapsed, refractory and histologically confirmed diagnosis of osteosarcoma (OST), neurobl
- * Is an individual of any sex/gender, ≥1 month to \<12 years of age for Part 1 and ≥1 month to \<18 years for Part 2 at the time of providing the informed consent or assent, as applicable
- * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.
- The main exclusion criteria include but are not limited to the following:
- * Has clinically significant corneal disease
- * Has a history of cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event within 6 months before screening
- * Has uncontrolled or significant cardiovascular disease, including conduction abnormalities, hypertension, ischemic heart disease, heart failure, and peripheral vascular disease
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07630974；登记信息更新于 2026-09-17。